新诊断胶质母细胞瘤海马保护VMAT放化疗可行性及失败模式分析
中位无进展生存9.7个月,总生存23.5个月;对侧海马及海马+1 cm失败率低(12个月无失败率97.2%和93.4%),且多伴随远处播散,提示该技术肿瘤学安全。
要点
- 对侧海马Dmax约束<17 Gy,中位剂量60 Gy/30次,未影响肿瘤学结局。
- 对侧海马及海马+1 cm失败率低,12个月无失败率分别为97.2%和93.4%。
- 对侧海马失败以室管膜下播散为主(66.7%),多伴弥漫进展。
核心结论
- 海马保护IMRT后对侧海马及海马+1 cm失败率极低,且多伴随弥漫性疾病进展,未损害肿瘤学结局。
主要发现
- 中位随访(存活者)11.7个月,中位无进展生存9.7个月,中位总生存23.5个月。
- 6例(7.3%)和8例(9.8%)患者最终分别在对侧海马和对侧海马+1 cm出现进展。
- 对侧海马及海马+1 cm的12个月无失败率分别为97.2%和93.4%。
- 初次进展时,对侧海马失败0例(0%),对侧海马+1 cm失败2例(2.4%)。
- 对侧海马失败的主要模式为室管膜下播散(66.7%)。
关键数值与推荐
- 对侧海马Dmax<17 Gy,海马保护IMRT中位剂量60 Gy/30次。
- 同侧海马剂量尽可能低。
临床怎么用
- 海马保护IMRT可用于预期生存较好的新诊断胶质母细胞瘤患者,不损害肿瘤学结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To identify the pattern of failure and oncological safety of hippocampus (HC)-sparing IMRT (HSRT) in newly diagnosed glioblastoma (GBM) patients. MATERIALS AND METHODS: Eighty-two GBM patients treated with temozolomide-based chemoradiation using HSRT between 2014 and 2018 were retrospectively reviewed. HSRT consisted of a sparing of Dmax of the contralateral HC < 17 Gy. Fifteen patients were unable to achieve the dose-constraints for adequate target coverage. The dose to ipsilateral HC was kept as low as possible. The pattern of failure was investigated, focusing on the area in the vicinity of the spared HC (organ and + 1 cm area). The median HSRT dose was 60 Gy in 30 fractions. RESULTS: The median follow-up for survivors was 11.7 months. The median progression-free and overall survival were 9.7 and 23.5 months, respectively. Six (7.3%) and eight (9.8%) patients eventually demonstrated progressive disease at the contralateral HC and HC + 1 cm, respectively. The 12-month contralateral HC and HC + 1 cm failure-free rate were 97.2 and 93.4%, respectively. However, no patient (0%) and two patients (2.4%) showed failure at contralateral HC and HC + 1 cm at initial progression, respectively. The dominant pattern of failure at the contralateral HC was by subependymal seeding (66.7%). CONCLUSION: The incidence of failure at the contralateral HC and HC + 1 cm is very low and mostly accompanied by disseminated disease progression after HSRT. Since HSRT does not compromise oncological outcomes, it could be considered especially for GBM patients who are expected to have favorable survival outcomes.
引用
- Wee CW, Kim KS, Kim CY, et al. Feasibility of hippocampus-sparing VMAT for newly diagnosed glioblastoma treated by chemoradiation: pattern of failure analysis. Radiat Oncol. 2020. PMID: 32375876. doi:10.1186/s13014-020-01552-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。